Cancer vaccine prevents deadly melanoma from returning or spreading in landmark trial

Merck and Moderna's mRNA cancer vaccine hit its Phase 3 trial endpoint, showing improved recurrence-free survival in melanoma patients after surgery.

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

CBS News medical correspondent Dr. Céline Gounder joins "The Daily Report" to discuss what Moderna's melanoma vaccine breakthrough could mean as clinical trials continue.

Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.

Moderna and Merck said the personalised vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment.

The candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.

A new personalised vaccine could halve the risk of skin cancer returning in high-risk patients, a large trial has found.

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

A trial of more than 1,100 patients finds a new experimental drug could prevent one of the deadliest forms of skin cancer from returning.

Moderna and Merck say the experimental vaccine prevented the return and spread of the cancer in high-risk melanoma patients.

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.   The positive results mean a potentially life-extending treatment is one step closer to being a

Landmark vaccine stops cancer returning in trial  The Times